FibroBiologics
FibroBiologics is a clinical-stage biotechnology company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. The company holds over 240 patents across various clinical pathways, including multiple sclerosis, cartilage repair, degenerative disc disease, cancer, wound healing, and life extension programs. It aims to revolutionize treatment paradigms for chronic diseases using its proprietary fibroblast platform, which is based on the most common cell in the human body, fibroblasts. The company is led by a team of experienced executives and scientific advisors, and is actively engaged in research, development, and clinical trials to bring innovative therapies to market.
Industries
Nr. of Employees
small (1-50)
FibroBiologics
Houston, Texas, United States, North America
Products
Pipeline of fibroblast-based therapeutic candidates
A portfolio of clinical-stage and preclinical fibroblast cell-based and fibroblast-derived product candidates targeting chronic diseases and regenerative indications such as multiple sclerosis, degenerative disc disease, wound healing, cancer, and thymic/splenic involution.
Pipeline of fibroblast-based therapeutic candidates
A portfolio of clinical-stage and preclinical fibroblast cell-based and fibroblast-derived product candidates targeting chronic diseases and regenerative indications such as multiple sclerosis, degenerative disc disease, wound healing, cancer, and thymic/splenic involution.
Services
Development of fibroblast-derived therapeutic candidates
Research and development services to discover, characterize and advance fibroblast-based therapeutic candidates toward clinical evaluation.
Laboratory-based assay and molecular characterization
Development and application of molecular assays (genomic, proteomic, epigenetic) to support product characterization and biomarker identification.
Development of fibroblast-derived therapeutic candidates
Research and development services to discover, characterize and advance fibroblast-based therapeutic candidates toward clinical evaluation.
Laboratory-based assay and molecular characterization
Development and application of molecular assays (genomic, proteomic, epigenetic) to support product characterization and biomarker identification.
Expertise Areas
- Fibroblast cell therapy development
- Preclinical and early clinical development
- Cell culture and cell therapy platform engineering
- Biomarker and molecular assay development
Key Technologies
- Fibroblast cell-based therapeutics
- Primary cell culture and differentiation
- Next-generation sequencing workflows
- Proteomics